Journal of Advances in Internal Medicine | Review Article
In addition to HCT-CI the PAM score has been described. 37 The PAM scores predicts mortality after transplant. Although it captures some comorbid conditions it is not specifically designed to evaluate comorbidities alone but rather all aspects associated with transplantation outcome that may contribute to increased morbidity and mortality. For example the PAM score includes disease related risk and type of donor.
Reduced InTensITy And non MyeloABlATIVe condITIonIng
Myeloablative (MAC) transplantation refers to conditioning which leads to severe and long lasting cytopenias which would not recover without stem cell infusion. 38 These regimens lead to rapid full donor chimerism but are generally thought to lead to greater NRM.
The realization that "immune-ablation" and not myeloablation was required for successful transplantation has lead to reduced intensity (RIC) and non myeloblative (NMA) transplant.
Although it is likely that RIC reduces antileukemic effect, 39 it is widely accepted that these regimens produce much less transplant related morbidity and mortality and therefore are often attractive in elderly and comorbid patients. In contrast to MAC, NMA conditioning cause minimal cytopenias which do not require stem cell support38. These regimens lessen NRM but still carry significant risk of acute graft versus host disease (aGVHD) which may be delayed in onset. If these 2 classes are considered at opposite ends of a spectrum then reduced intensity conditioning falls in the middle ground. For RIC, autologous reconstitution remains a possibility. There are now multiple phase II and retrospective studies with a multitude of NMA and RIC regimens. Although large prospective multicenter trials are ongoing, data on the full impact of these regimens or indeed whether any one is superior to another is currently lacking. were 36%, 36%, 42% and 46% respectively. Therefore even though the use of low dose TBI with fludarabine is well tolerated it often leads to failure to engraft as well as a high relapse rate in myeloid malignancies. The addition of a further 2 Gy to above described 2Gy/ fludarabine regimen has been attempted in an effort to decrease graft rejection and disease relapse. These data were compared with the authors data from previous experience with 2Gy TBI.
Although fewer 4Gy TBI patients experienced graft rejection than that observed for the 2Gy TBI group, this did not reach statistical significance. No difference in relapse rate or survival were noted between the 2 groups, however many patients had indolent lymphoid malignancies rather than more aggressive myeloid malignancies. In subgroup analyses it appeared that patients with myeloid malignancies benefited most in terms of improved survival although patient numbers were small. Importantly the additional 2Gy was well tolerated. 42 An alternative NMA regimen has been proposed by the Stanford group involving total lymph node irradiation and antithymocyte globulin. 43 The analysis included 47 patients with myeloid malignancies. In total 34 patients were over the age of 60 years of age. 1 year NRM was less than 4%. 3 year OS was 60%. Therefore relapse remained a significant cause of death.
RIC has been described utilizing a fludarabine immunosuppressive backbone in addition to alkylator therapy with melphalan (<140mg/ m2). The fludarabine/ melphalan regimen has now been described by several groups to have acceptable non relapse mortality [44] [45] [46] [47] [48] One of the initial descriptions of this regimen was by the MD Anderson group utilizing fludarabine (125mg/m2) and melphalan (140mg/ m2 or 180mg/m2). 44 In patients with a median age of 52 years the NRM was 37.4% at 100 days. Overall survival was not adversely to TBI based regimens with decreased toxicity 56 In addition targeting of busulfan dose has gained acceptance as low busulfan levels have been shown to correlate with relapse. 57 The fludarabine/ busulfan regimen was described by Russel et al in 2002. The authors described a tolerable regimen with reliable engraftment58. We have described that a standard RIC regimen (Fludarabine/ Melphalan) and MAC (Fludarabine/ Busulfan) induced similar hematologic and minimal extrahematologic toxicity. 59 Furthermore, the outcome of patients at standard risk and high risk was comparable to other standard regimens, but with a reduced toxicity 60 An improving knowledge of busulfan pharmacokinetics has allowed many centers to design strategies using low, intermediate or full dose busulfan. [52] [53] [54] [55] [61] [62] [63] The optimal dose for reduced intensity regimens including busulfan has been addressed by in a study comparing 3.2mg/kg with 6.4mg/ kg64. Median age of patients was 58 in the lower dose group and 62 in the higher dose group (p=0.0006). 2 year NRM was 3.7% in the low dose group and 11.1% in the high dose group (p<0.05).
However relapse was significantly increased in the low dose group.
New strategies targeting the dose of Bu according to PK studies at the time of transplant are currently addressing whether efficacy and toxicity may be optimized in each patient avoiding sub-or supratherapeutic levels of busulfan.
Clinical experience with transplantation in elderly patients with AML
A number of small single center studies have shown safety of allo-SCT in elderly patients. However, evidence presented in large cohorts of patients (Table 2 ) now supports the safety and efficacy of allo-SCT in elderly patients with AML. 65, 66 The European Group for Blood and Marrow Transplantation (EBMT) reported on 1333 MDS and secondary AML patients over the age of 50, including 34% over 60 years of age, who received a transplant after 1998. 62% were conditioned with RIC and 38% with MAC. In multivariate analysis age >60 did not impact overall survival or non relapse mortality.
Advanced disease, RIC and unrelated donor were risks for non relapse mortality. The major independent variable for overall survival was disease stage at time of transplantation. A CIBMTR analysis included a total of 1080 patients. Of these 545 patients had AML (the remainder had MDS). Among patients with AML, 36% were older than 60 years of age, and 12% were ≥ 65 years old. In multivariate analysis recipient age was not an independent variable for non re- 
